InfinixBio’s VP of Pharmacokinetics, Craig McElroy, Ph.D., is partnering with Mark Hester, PhD, principal investigator in the Institute for Genomic Medicine (IGM) at Nationwide Children’s Hospital, on a potentially transformative gene therapy for the treatment of Tuberous Sclerosis Complex Type 2 (TSC2).
Affecting approximately 2 million people worldwide, TSC is a life-threatening genetic disease, typically diagnosed in infants and young children. For more information on this groundbreaking work, click HERE.
Our experienced lab team is here to help. Reach out today to learn more.
Back to Blog
